Honouring research excellence: Dr Sam Behjati wins award for work to unravel the identity and origin of childhood cancers

The 2019 recipient of the Dr Simon Newell Early Career Investigator Award has been announced as Dr Sam Behjati, whose career to date has focused on the developmental origins of childhood cancers

Honouring research excellence: Dr Sam Behjati wins award for work to unravel the identity and origin of childhood cancers

Dr Sam Behjati has received the Royal College of Paediatrics and Child Health (RCPH) Dr Simon Newell Early Career Investigator Award
Dr Sam Behjati has received the Royal College of Paediatrics and Child Health (RCPH) Dr Simon Newell Early Career Investigator Award. Image credit: Wellcome Sanger Institute

Since 1999, Sparks charity has funded the Dr Simon Newell award along with the Royal College of Paediatrics and Child Health (RCPCH) to recognise excellence in child health research. GOSH Charity has co-supported the award since 2017. This annual honour is open to outstanding clinician researchers early in their academic career, and is named in memory of Dr Simon Newell – a renowned and widely respected neonatologist and paediatrician who had a passion for encouraging the next generation of paediatric clinicians and researchers.

This year’s recipient Dr Behjati is Group Leader in Cellular Genetics at the Wellcome Sanger Institute, one of the world’s leading genome and biodata institutes. He is also a Consultant Paediatric Oncologist at Addenbrooke’s Hospital in Cambridge, where he looks after children with cancer. He was nominated by Professor Kathy Pritchard-Jones and is described as one of the country’s most successful paediatric scientists and a key player in childhood cancer research.

Dr Behjati’s research is focused on understanding how and why childhood cancer happens. Using state-of-the-art technologies to ‘read’ the unique genetic code hidden inside cells, he hopes to identify the exact point in a child’s development when cancer cells form. In a high-profile study published last year Dr Behjati and his team used cutting-edge techniques to study the genetic code inside individual microscopic kidney cells, and compared these healthy sequences with those from children and adults with a type of kidney cancer known as Wilms’ tumour.

Wilms’ is the most common type of kidney cancer in children. It happens when something goes wrong as a child is developing in the womb and some of their immature kidney cells don't turn into fully formed kidney cells. If this happens, those cells begin to grow out of control and can develop into a Wilms’ tumour.

Dr Behjati’s research identified the exact point in a kidney cell’s maturation process where these faulty cells develop. Critical information like this about Wilms’ tumour and other childhood cancers could offer opportunities to mature, rather than kill, cancer cells.  This could potentially lead to kinder, less aggressive and potentially even more effective treatments.

“I am delighted to see Sam’s exemplary efforts in the area of childhood cancer research recognised. Research is fundamentally important to help us find new, kinder treatments, and cures, for those children with rare and complex conditions, like childhood cancers. I congratulate Sam on receiving this award and look forward to seeing the development of his exciting research in the future.”

Kiki Syrad – who is Director of Grants & Impact for both GOSH Charity and its partner charity Sparks 

“Child health research lays the foundation for the future health of our nation and with over 1,800 new cases of cancer diagnosed in children per year in 2013-15 in the UK, Sam’s dedication to this area of research in particular, will benefit families and health colleagues for many now and in years to come.

“Sam is a role model for the next generation of paediatricians and I congratulate him on winning this well-deserved award.”

Professor Russell Viner, President of the Royal College of Paediatrics and Child Health (RCPCH) 

“I feel very honoured to receive this recognition by my colleagues.”

Dr Sam Behjati, Group leader of the Cancer genomics & single cell transcriptomics team, at the Wellcome Sanger Institute

Dr Simon Newell was connected to Sparks throughout his career, first as a researcher, then as a member of the Medical Advisory Committee, and later as a Trustee. This award has been named in his memory, as recognition of his tremendous contribution to child health research, and is worth £2000. 

Notes to Editors
Selected Websites
Caring for children with cancerSanger LifeCaring for children with cancer
We explore the world of award-winning cancer scientist, Dr Sam Behjati

Is cancer a genetic disease?FactsIs cancer a genetic disease?
Cancer is the most common human genetic disease. The transition from a normal cell to a malignant cancer is driven by changes to a cell’s DNA, also known as mutations.

Pharmacogenomics and cancerStoriesPharmacogenomics and cancer
Pharmacogenomics is a specific kind of genetic testing that offers key advantages for doctors trying to choose the best drugs for their patients. 

Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

Appointments and changes to the Genome Research Limited Board
At the GRL Board meeting on 2 December 2019, David Willetts announced his intention to step down as Chair because of his extensive commitments across the academic and science sectors. Wellcome's Director, Jeremy Farrar, will take over the Chair of GRL Board from 1 January 2020.
Researchers identify new possibilities for the treatment of inflammatory bowel disease
Two molecular pathways found to be integral to maintaining balance in the digestive system
Root of childhood kidney cancer discovered
Pre-cancerous signatures found in healthy tissue point the way towards new treatment options